



HASKELL ADLER, PH.D.,MBA

Sr. Licensing Manager

Office of Innovation and Industry Alliances

Moffitt Cancer Center

Haskell is currently Senior Licensing Manager at the Moffitt Cancer Center, where he helps researchers and clinicians patent and license their inventions, and form startups around Moffitt technologies. Haskell became a registered patent agent with the U.S. Patent and Trademark Office in 2016.

Haskell was previously a Licensing Manager at the University of Georgia before joining Moffitt. Haskell was also a Science Advisor in the Intellectual Property Practice of the law firm Needle & Rosenberg, and then Ballard Spahr after it acquired Needle & Rosenberg. He was a member of the biotechnology, pharmaceutical, medical device, and litigation practice groups, where he focused primarily on patent prosecution. Haskell joined the law firm after a number of years working as a Principal at Georgia Venture Partners, an early-stage biomedical Venture Capital Fund. Haskell structured financial deal terms for equity and debt investments, wrote business plans, and negotiated license agreements, in addition to being the Interim CEO of Axona Inc, a Georgia Venture Partners portfolio company developing drugs for chemotherapy-induced peripheral neuropathy.

Prior to Georgia Venture Partners, Haskell was an analyst at both Kilkenny Capital Management and S Squared Technology Corporation, hedge funds that specialized in biomedical securities where he covered the small- to mid-cap growth stocks, and focused on companies whose main products were in the clinical developmental process. Earlier in his career, Haskell was a researcher at the VA Medical Center in Seattle, where he studied human leukemia genes.

Haskell holds an MBA in finance from the Yale School of Management, a PhD in chemistry from the University of California at San Diego and the Salk Institute, and a BA with a double major in chemistry and physics from Cornell University.